bhupendra    on May 28, 2011 Says : good

Tags : Ren Fail. 2007;29(8):961-6  

Tags :

Reference : 1. Sy Theodore, Jamal MM: Epidemiology of hepatitis C virus (HCV) infection. Int J. Med. Sci. 2006;    more

Reference : 1. Sy Theodore, Jamal MM: Epidemiology of hepatitis C virus (HCV) infection. Int J. Med. Sci. 2006; 3:41-45 2. Muir AJ, Bornstein JD, Killenberg PG: Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350:2265-2271 3. Nakayama E, Akiba T, Marumo F, et al.: Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000; 11:1896-1902 4. Stehman-Breen CO, Emerson S, Gretch D, et al.: Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis 1998; 32:629-634 5. Izopet J, Sandres-Saune K, Kamar N, et al.: Incidence of HCV infection in French hemodialysis units: a prospective study. J Med Virol 2005; 77:70-76 6. Manangan LP, Pearson ML, Tokars JI, et al.: Feasibility of national surveillance of health-care-associated infections in home-care settings. Emerg Infect Dis 2002; 8:233-236 7. Salama G, Rostaing L, Sandres K, et al.: Hepatitis C virus infection in French hemodialysis units: a multicenter study. J Med Virol 2000; 61:44-51 8. Schneeberger PM, Keur I, van der Vliet W, et al.: Hepatitis C virus infections in dialysis centers in The Netherlands: a national survey by serological and molecular methods. J Clin Microbiol 1998; 36:1711-1715 9. Tokars JI, Frank M, Alter MJ, et al.: National surveillance of dialysis-associated diseases in the United States, 2000. Semin Dial 15:162-171, 2002 10. Fabrizi F, Poordad FF, Martin P: Hepatitis C Infection and the patient with end-stage renal disease. Hepatology 2002; 36:3-10 11. Dzekova P, Slavkovska A, Simjanovska L, et al.: Prevalence of hepatitis C virus infection in dialysis patients. BANTAO Journal 2006; 4:6-7 12. Meyers CM, Seeff LB, Stehman-Breen CO, et al.: Hepatitis C and renal disease: an update. Am J Kidney Dis 2003; 42:631-657 13. Fabrizi F, Dulai G, Dixit V, et al.: Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003; 18:1071-1081 14. Russo MW, Goldsweig CD, Jacobson IM, et al.: Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 2003; 98:1610-1615 15. Heathcote EJ, Shiffman ML, Cooksley WG, et al.: Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343:1673-1680 16. Zeuzem S: Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140:370-381 17. Zeuzem S, Feinman SV, Rasenack J, et al.: Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343:1666-1672 18. Bruchfeld A, Lindahl K, Reichard O, et al.: Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006; 13:316-321 19. Russo MW, Ghalib R, Sigal S, et al.: Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2006; 21:437-443 20. Hoofnagle JH, di Bisceglie AM: The treatment of chronic viral hepatitis. N Engl J Med 1997; 336:347-356 21. McHutchison JG, Gordon SC, Schiff ER, et al.: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-1492 22. Sporea I, Popescu A, Sirli R, et al.: Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis. World J Gastroenterol 2006; 12:4191-4194 23. Rostaing L, Chatelut E, Payen JL, et al.: Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998; 9:2344-2348 24. Pawlotsky JM: Therapy of hepatitis C: from empiricism to eradication. Hepatology 2006; 43:(Suppl 1):207-220 25. Teta D, Luscher BL, Gonvers JJ, et al.: Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. Nephrol Dial Transplant 2005; 20:991-993 26. Rivera M, Gentil MA, Sayago M, et al.: Treatment of hepatitis C virus with interferon in hemodialysis patients awaiting kidney transplant. Transplant Proc 2005; 37:1424-1425 27. La-Roche H: Pegasys Treatment Algorithm for Healtcare professionals. . http://www.pegasys.com/hcp/tools.aspx, 2006    less

Abstract : Background. The high prevalence of hepatitis C virus (HCV) infection in hemodialysis patients is of    more

Abstract : Background. The high prevalence of hepatitis C virus (HCV) infection in hemodialysis patients is of great concern because they have a higher rate of mortality than HCV negative hemodialysis patients. The aim of the study was to evaluate the efficacy and safety of pegylated interferon a-2a monotherapy in hemodialysis patients with chronic HCV infection. Methods. Fourteen dialysis patients with chronic HCV infection were scheduled to receive 135µg pegylated interferon a-2a, subcutaneously, once a week, after dialysis session for a period of 48 weeks. Efficacy and safety were assessed by: end of treatment viral response, sustained viral response, biochemical response, and adverse events. Serum HCV RNA levels were assessed using reverse transcriptase polymerase chain reaction (RT-PCR), while HCV genotype was analyzed by RT-PCR followed by hybridization of amplified products. Results. From the total of 14 patients enrolled in the study, 9 completed treatment. Eight patients (57%) had undetectable levels of HCV RNA at the end of treatment, while one patient remained positive. Two (14.3%) patients were discontinued because of insufficient therapeutic response. Three patients (21.34%) did not finish treatment because serious adverse events occurred: one patient with bronchopneumonia and one with pericarditis were discontinued from treatment, while one patient died due to cerebral hemorrhage. Sustained viral response was present in 36% of the patients (5/8 patients) at the end of the follow up period. Biochemical response with normalization of serum ALT levels during treatment was observed in all treated patients (83±20.1 U/L at base line vs. 23.4±4.6 U/L at week 48). The most common adverse events were flu-like syndrome, myalgia, arthralgia, and pancytopenia. Most of the adverse events were manageable. The serious adverse events were believed to be unrelated to the therapy, but rather to the co-morbidities of the hemodialysis patients. Conclusions. Pegylated interferon a-2a treatment was effective in a considerable proportion of the treated hemodialysis patients with hepatitis C, and it was reasonably safe to use. key words: adverse events, hemodialysis, hepatitis C, pegylated interferon a-2a, renal failure chronic - Slides    less